This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Alphatec Spine, Inc. Releases PureGen(TM) Osteoprogenitor Cell Allograft To Facilitate Bone Regeneration And Announces First Patient Procedure Performed In The World

CARLSBAD, Calif., Oct. 5, 2010 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine, today announced the release of its PureGen Osteoprogenitor Cell Allograft at the North American Spine Society Meeting (NASS) in Orlando, FL. PureGen is a highly concentrated, pure population of adult stem cells that originates in bone marrow and is collected from live, healthy donors for optimal cell functionality. Unlike stem cell products that are currently commercially available, which have an unknown population of mesenchymal stem cells (MSCs) and are harvested from cadaveric donor tissue, PureGen delivers a similar potency of a pure adult MSCs without the need for cultural expansion. PureGen is the first pure adult stem cell to be released in the spinal market.

Dr. Carl Lauryssen, a Neurosurgeon and Director of Research and Education at Olympia Medical Center in Los Angeles, CA, completed the first procedure using PureGen. Pablo Pazmino, M.D. assisted in the surgery. Dr. Lauryssen has twice been awarded the Young Investigator Award from the American Association of Neurological Surgeons for his work on cervical disorders and stem cell research. The patient underwent a L4-S1 posterolateral fusion. "I believe in the promise of stem cells for treating spinal disorders as they pose minimal inflammatory side effects and have the capacity to repair and regenerate bone. I also believe the PureGen cell has the potential for providing surgeons with better clinical outcomes in spinal fusion," stated Dr. Lauryssen. 

"We are committed to developing meaningful biologics solutions to improve surgical outcomes in the spine market, and this exciting new stem cell product has an enormous amount of potential. The PureGen osteoprogenitor cell is an extremely powerful cell that has both pluripotent potential and osteogenic differentiation. Our preclinical results underscore the ability of this cell to differentiate to bone faster and more efficiently than either bone marrow aspirate or mesenchymal stem cells," said Dirk Kuyper, the Company's President and CEO.  Mr. Kuyper added, "It's exciting to add this significantly differentiated product to our portfolio. The PureGen osteoprogenitor cell will provide Alphatec Spine with an excellent position in the growing market of stem cell therapies for treating disorders of the spine, and will be a strong complement to the other innovative technologies in our core fusion and aging spine portfolios."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs